Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MALARIA-094
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Jun 2018 Planned End Date changed from 25 Nov 2022 to 15 Dec 2022.
    • 26 Mar 2018 Planned End Date changed from 15 Dec 2022 to 25 Nov 2022 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top